135 related articles for article (PubMed ID: 15990709)
1. [Effects of a new pharmacological complex (silybin + vitamin-E + phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study].
Trappoliere M; Federico A; Tuccillo C; de Sio I; Di Leva A; Niosi M; D'Auria M; Loguercio C;
Minerva Gastroenterol Dietol; 2005 Jun; 51(2):193-9. PubMed ID: 15990709
[TBL] [Abstract][Full Text] [Related]
2. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study.
Loguercio C; Federico A; Trappoliere M; Tuccillo C; de Sio I; Di Leva A; Niosi M; D'Auria MV; Capasso R; Del Vecchio Blanco C;
Dig Dis Sci; 2007 Sep; 52(9):2387-95. PubMed ID: 17410454
[TBL] [Abstract][Full Text] [Related]
3. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations.
Federico A; Trappoliere M; Tuccillo C; de Sio I; Di Leva A; Del Vecchio Blanco C; Loguercio C
Gut; 2006 Jun; 55(6):901-2. PubMed ID: 16698763
[No Abstract] [Full Text] [Related]
4. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
Loguercio C; Andreone P; Brisc C; Brisc MC; Bugianesi E; Chiaramonte M; Cursaro C; Danila M; de Sio I; Floreani A; Freni MA; Grieco A; Groppo M; Lazzari R; Lobello S; Lorefice E; Margotti M; Miele L; Milani S; Okolicsanyi L; Palasciano G; Portincasa P; Saltarelli P; Smedile A; Somalvico F; Spadaro A; Sporea I; Sorrentino P; Vecchione R; Tuccillo C; Del Vecchio Blanco C; Federico A
Free Radic Biol Med; 2012 May; 52(9):1658-65. PubMed ID: 22343419
[TBL] [Abstract][Full Text] [Related]
5. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.
Grattagliano I; Diogo CV; Mastrodonato M; de Bari O; Persichella M; Wang DQ; Liquori A; Ferri D; Carratù MR; Oliveira PJ; Portincasa P
World J Gastroenterol; 2013 May; 19(20):3007-17. PubMed ID: 23716980
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients.
Federico A; Dallio M; Masarone M; Gravina AG; Di Sarno R; Tuccillo C; Cossiga V; Lama S; Stiuso P; Morisco F; Persico M; Loguercio C
Oxid Med Cell Longev; 2019; 2019():8742075. PubMed ID: 31737175
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
Fartoux L; Poujol-Robert A; Guéchot J; Wendum D; Poupon R; Serfaty L
Gut; 2005 Jul; 54(7):1003-8. PubMed ID: 15951550
[TBL] [Abstract][Full Text] [Related]
11. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Bugianesi E; Bouserhal T; Marini F; Ridolfi F; Tarsetti F; Ancarani F; Petrelli E; Peruzzi E; Lo Cascio M; Rizzetto M; Marchesini G; Benedetti A
Gut; 2007 Sep; 56(9):1296-301. PubMed ID: 17392334
[TBL] [Abstract][Full Text] [Related]
12. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats.
Di Sario A; Bendia E; Taffetani S; Omenetti A; Candelaresi C; Marzioni M; De Minicis S; Benedetti A
Dig Liver Dis; 2005 Nov; 37(11):869-76. PubMed ID: 16169303
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.
Enjoji M; Kotoh K; Kato M; Higuchi N; Kohjima M; Nakashima M; Nakamuta M
Int J Mol Med; 2008 Oct; 22(4):521-7. PubMed ID: 18813860
[TBL] [Abstract][Full Text] [Related]
14. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
[TBL] [Abstract][Full Text] [Related]
15. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
[TBL] [Abstract][Full Text] [Related]
16. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
17. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.
Halfon P; Pénaranda G; Carrat F; Bedossa P; Bourlière M; Ouzan D; Renou C; Tran A; Rosenthal E; Wartelle C; Delasalle P; Cacoub P
Aliment Pharmacol Ther; 2009 Jul; 30(1):61-70. PubMed ID: 19292832
[TBL] [Abstract][Full Text] [Related]
18. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
Rafiq N; Younossi ZM
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and vascular effects of silybin in hypertensive patients with high 1-h post-load plasma glucose.
Sciacqua A; Perticone M; Tripepi G; Addesi D; Cassano V; Maio R; Sesti G; Perticone F
Intern Emerg Med; 2019 Jan; 14(1):77-84. PubMed ID: 30232738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
